Manos Perros

3.4k citations

38 papers · 2.8k · 1 hit paper · h-index 22

Impact in

Virology top 0.5%
- HIV Research and Treatment
Infectious Diseases top 2%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in

Virology 22
- HIV Research and Treatment 22
Infectious Diseases 21
- HIV/AIDS drug development and treatment 18

Co-authors: Mike Westby (10 shared papers)Patrick K. Dorr (7 shared papers)Julie Mori (3 shared papers)Caroline Smith‐Burchnell (3 shared papers)Anthony Wood (10 shared papers)Rob Webster (5 shared papers)Blanda Stammen (5 shared papers)Duncan R. Armour (5 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (6 papers)Journal of Virology (5 papers)Antimicrobial Agents and Chemotherapy (5 papers)Antiviral Research (2 papers)Journal of Medicinal Chemistry (2 papers)
Partner nations: United Kingdom United States France

In The Last Decade

Manos Perros

38 papers receiving 2.7k citations

Manos Perros's Hit Papers

align trajectories log scale

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity 2005 · 965 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2005 Antimicrobial Agents and Chemotherapy

Peers

Countries citing papers authored by Manos Perros

Since Specialization

Citations

This map shows the geographic impact of Manos Perros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manos Perros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manos Perros more than expected).

Fields of papers citing papers by Manos Perros

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manos Perros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manos Perros. The network helps show where Manos Perros may publish in the future.

Co-authors

The 25 scholars most cited alongside Manos Perros, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Manos Perros Line = papers co-authored together Manos Perros links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity Antimicrobial Agents and Chemotherapy ·Patrick K. Dorr, Mike Westby, Susan Dobbs, Paul Griffin, Becky Irvine, Malcolm J. Macartney, Julie Mori, Graham Rickett Hit paper breakdown →	2005	965
2	Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry Journal of Virology ·Mike Westby, Caroline Smith‐Burchnell, Julie Mori, Marilyn Lewis, Michael J. Mosley, Mark Stockdale, Patrick K. Dorr, Giuseppe Ciaramella	2006	290
3	Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir Journal of Virology ·Mike Westby, Marilyn Lewis, Jeannette M. Whitcomb, Mike S Youle, Anton Louis Pozniak, Ian James, Tim M. Jenkins, Manos Perros	2006	274
4	HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention PLoS Pathogens ·Wade S. Blair, Chris Pickford, Stephen L. Irving, David Brown, Marie D. Anderson, Richard Bazin, Joan Q. Cao, Giuseppe Ciaramella	2010	256
5	Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases Scientific Reports ·Gregory S. Basarab, Gunther H. Kern, John M. McNulty, John P. Mueller, Kenneth R Lawrence, Karthick Vishwanathan, Richard A. Alm, Kevin Barvian	2015	96
6	Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development Candidate Bioorganic & Medicinal Chemistry Letters ·Charles E. Mowbray, Catherine Burt, Romuald Corbau, Simon Gayton, Michael L. Hawes, Manos Perros, Isabelle Tran, David A. Price	2009	93
7	Untargeted Metabolomics To Ascertain Antibiotic Modes of Action Antimicrobial Agents and Chemotherapy ·Isabel M. Vincent, David E. Ehmann, Scott D. Mills, Manos Perros, Michael Peter Barrett	2016	74
8	The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691) Clinical Pharmacology & Therapeutics ·Mark D. Fidock, B E Souberbielle, Carl D. Laxton, Jaiessh K. Rawal, Oona E Delpuech-Adams, T Corey, Peter Colman, Vinay Kumar	2011	67
9	Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc Bioorganic & Medicinal Chemistry Letters ·David A. Price, Duncan R. Armour, Marcel de Groot, Derek J. Leishman, Carolyn M. Napier, Manos Perros, Blanda Stammen, Anthony Wood	2006	57
10	New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation Antimicrobial Agents and Chemotherapy ·Wade S. Blair, Joan Q. Cao, Juin Fok‐Seang, Paul Griffin, Jason Isaacson, Raven Jackson, Edward J. Murray, Amy K. Patick	2009	53
11	Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1 Antimicrobial Agents and Chemotherapy ·Romuald Corbau, Julie Mori, Chris Phillips, Lesley Fishburn, Alex Martín, Charles E. Mowbray, Wendy Panton, Caroline Smith‐Burchnell	2010	53
12	A sustainable model for antibiotics Science ·Manos Perros	2015	47
13	Novel Indazole Non-Nucleoside Reverse Transcriptase Inhibitors Using Molecular Hybridization Based on Crystallographic Overlays Journal of Medicinal Chemistry ·Lyn H. Jones, Gill A. Allan, Oscar Barba, Catherine Burt, Romuald Corbau, Thomas Dupont, Thorsten Knöchel, Steve Irving	2009	45
14	An Imidazopiperidine Series of CCR5 Antagonists for the Treatment of HIV: The Discovery of N-{(1S)-1-(3-Fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798) Journal of Medicinal Chemistry ·Paul A. Stupple, David V. Batchelor, Martin Corless, Patrick K. Dorr, David A. Ellis, David R. Fenwick, Sébastien R. G. Galan, Rhys Jones	2010	36
15	Development and Automation of a 384-Well Cell Fusion Assay to Identify Inhibitors of CCR5/CD4-Mediated HIV Virus Entry SLAS DISCOVERY ·Joe Bradley, Jasween Gill, François Bertelli, Sara Letafat, Romu Corbau, Paul M. Hayter, Paula Harrison, Andy Tee	2004	32
16	Pyrazole NNRTIs 1: Design and initial optimisation of a novel template Bioorganic & Medicinal Chemistry Letters ·Charles E. Mowbray, Catherine Burt, Romuald Corbau, Manos Perros, Isabelle Tran, Paul A. Stupple, Rob Webster, Anthony Wood	2009	31
17	Pyrazole NNRTIs 3: Optimisation of physicochemical properties Bioorganic & Medicinal Chemistry Letters ·Charles E. Mowbray, Romuald Corbau, Michael L. Hawes, Lyn H. Jones, James E. J. Mills, Manos Perros, Matthew D. Selby, Paul A. Stupple	2009	26
18	Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics Drug Discovery Today ·David Altarac, Michael Gutch, John P. Mueller, Matthew D. Ronsheim, Rubén Tommasi, Manos Perros	2021	26
19	NF-Y controls transcription of the minute virus of mice P4 promoter through interaction with an unusual binding site Journal of Virology ·Zhenfang Gu, Serge Plaza, Manos Perros, Celina Cziepluch, Jean Rommelaere, Jan J. Cornelis	1995	25
20	A Low-Molecular-Weight Entry Inhibitor of both CCR5- and CXCR4-Tropic Strains of Human Immunodeficiency Virus Type 1 Targets a Novel Site on gp41 Journal of Virology ·Edward J. Murray, Daniel P. Leaman, Nishant Pawa, Hannah T. Perkins, Chris Pickford, Manos Perros, Michael B. Zwick, Scott L. Butler	2010	25

About Manos Perros

Manos Perros is a scholar working on Virology, Infectious Diseases, Immunology, Epidemiology and Animal Science and Zoology, having authored 38 papers that have together received 2.8k indexed citations. Recurring topics across this work include HIV Research and Treatment (22 papers), HIV/AIDS drug development and treatment (18 papers), Immune Cell Function and Interaction (10 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Animal Virus Infections Studies (3 papers), Pneumocystis jirovecii pneumonia detection and treatment (3 papers), Virus-based gene therapy research (3 papers) and Cancer therapeutics and mechanisms (3 papers). The work is most often cited by research in Virology (1.6k citations), Infectious Diseases (1.2k citations), Immunology (467 citations), Hepatology (150 citations) and Molecular Medicine (67 citations). Manos Perros has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Mike Westby, Patrick K. Dorr, Julie Mori, Caroline Smith‐Burchnell, Anthony Wood, Rob Webster, Blanda Stammen, Duncan R. Armour, Carolyn M. Napier and Marilyn Lewis. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Virology, Antimicrobial Agents and Chemotherapy, Antiviral Research and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Manos Perros

Impact in

Papers in i

In The Last Decade

Manos Perros

Manos Perros's Hit Papers

Peers

Countries citing papers authored by Manos Perros

Fields of papers citing papers by Manos Perros

All Works

About Manos Perros

Explore authors with similar magnitude of impact

Papers in